PURPOSE: Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: AML patients age 60 years and older in first complete remission after induction and consolidation chemotherapy were randomly assigned to no further therapy or a 90-day regimen of 14-day cycles of low-dose rIL-2, aimed at expanding natural killer (NK) cells, followed by 3-day higher doses aimed at activating cytotoxicity of expanded NK cells to lyse residual AML cells. All randomly assigned patients were included in an intention-to-treat analysis. RESULTS:A total of 163 (64%) of 254 patients who completed induction and consolidation chemotherapy on CALGB 9720 were randomly assigned to rIL-2 (n = 81) or no further therapy (n = 82); the most common reasons for lack of random assignment were patient refusal and relapse. Fifteen patients randomly assigned to rIL-2 never initiated it because of refusal, intercurrent medical problems, or relapse, and 24 patients initiated rIL-2 but stopped early because of toxicity or relapse. Grade 4 toxicities during rIL-2 therapy included thrombocytopenia (65%) and neutropenia (64%), and grade 3 toxicities included anemia (33%), infection (24%) and malaise/fatigue (14%). Forty-two patients (52%) randomly assigned to rIL-2 completed the full 90-day course. Patients in both arms had similar distributions of both disease-free (combined median = 6.1 months; P = .47) and overall survival (combined median = 14.7 months; P = .61) after random assignment. Moreover, the 42 patients who completed all planned therapy did not show prolongation of disease-free or overall survival. CONCLUSION: Low-dose rIL-2 maintenance immunotherapy is not a successful strategy in older AML patients.
RCT Entities:
PURPOSE:Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: AMLpatients age 60 years and older in first complete remission after induction and consolidation chemotherapy were randomly assigned to no further therapy or a 90-day regimen of 14-day cycles of low-dose rIL-2, aimed at expanding natural killer (NK) cells, followed by 3-day higher doses aimed at activating cytotoxicity of expanded NK cells to lyse residual AML cells. All randomly assigned patients were included in an intention-to-treat analysis. RESULTS: A total of 163 (64%) of 254 patients who completed induction and consolidation chemotherapy on CALGB 9720 were randomly assigned to rIL-2 (n = 81) or no further therapy (n = 82); the most common reasons for lack of random assignment were patient refusal and relapse. Fifteen patients randomly assigned to rIL-2 never initiated it because of refusal, intercurrent medical problems, or relapse, and 24 patients initiated rIL-2 but stopped early because of toxicity or relapse. Grade 4 toxicities during rIL-2 therapy included thrombocytopenia (65%) and neutropenia (64%), and grade 3 toxicities included anemia (33%), infection (24%) and malaise/fatigue (14%). Forty-two patients (52%) randomly assigned to rIL-2 completed the full 90-day course. Patients in both arms had similar distributions of both disease-free (combined median = 6.1 months; P = .47) and overall survival (combined median = 14.7 months; P = .61) after random assignment. Moreover, the 42 patients who completed all planned therapy did not show prolongation of disease-free or overall survival. CONCLUSION: Low-dose rIL-2 maintenance immunotherapy is not a successful strategy in older AMLpatients.
Authors: D Blaise; M Attal; J Reiffers; M Michallet; C Bellanger; J L Pico; A M Stoppa; C Payen; G Marit; R Bouabdallah; J J Sotto; J F Rossi; M Brandely; T Hercend; D Maraninchi Journal: Eur Cytokine Netw Date: 2000-03 Impact factor: 2.737
Authors: Sherif S Farag; Stephen L George; Edward J Lee; Maria Baer; Richard K Dodge; Brian Becknell; Todd A Fehniger; Lewis R Silverman; Jeffrey Crawford; Clara D Bloomfield; Richard A Larson; Charles A Schiffer; Michael A Caligiuri Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Jacob M Rowe; Donna Neuberg; William Friedenberg; John M Bennett; Elisabeth Paietta; Adel Z Makary; Jane L Liesveld; Camille N Abboud; Gordon Dewald; F Ann Hayes; Martin S Tallman; Peter H Wiernik Journal: Blood Date: 2003-09-25 Impact factor: 22.113
Authors: Maria R Baer; Stephen L George; Richard K Dodge; Kieran L O'Loughlin; Hans Minderman; Michael A Caligiuri; John Anastasi; Bayard L Powell; Jonathan E Kolitz; Charles A Schiffer; Clara D Bloomfield; Richard A Larson Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: M T Fierro; X S Liao; P Lusso; M Bonferroni; L Matera; A Cesano; P Lista; R Arione; G Forni; R Foa Journal: Leukemia Date: 1988-01 Impact factor: 11.528
Authors: Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski Journal: Blood Date: 2011-04-25 Impact factor: 22.113
Authors: Guido Marcucci; Kati S Maharry; Klaus H Metzeler; Stefano Volinia; Yue-Zhong Wu; Krzysztof Mrózek; Deedra Nicolet; Jessica Kohlschmidt; Susan P Whitman; Jason H Mendler; Sebastian Schwind; Heiko Becker; Ann-Kathrin Eisfeld; Andrew J Carroll; Bayard L Powell; Jonathan E Kolitz; Ramiro Garzon; Michael A Caligiuri; Richard M Stone; Clara D Bloomfield Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Bhavana Bhatnagar; Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Dimitrios Papaioannou; Christopher J Walker; Shelley Orwick; James S Blachly; Jonathan E Kolitz; Bayard L Powell; Andrew J Carroll; Richard M Stone; John C Byrd; Clara D Bloomfield Journal: Leukemia Date: 2019-08-28 Impact factor: 11.528
Authors: Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio Journal: Blood Date: 2016-06-27 Impact factor: 22.113
Authors: Meagan A Jacoby; Michael G Martin; Geoffrey L Uy; Peter Westervelt; John F Dipersio; Amanda Cashen; Keith Stockerl-Goldstein; Ravi Vij; Jingqin Luo; Teresa Reineck; Noel Bernabe; Camille N Abboud Journal: Am J Hematol Date: 2014-03-03 Impact factor: 10.047
Authors: Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield Journal: Clin Cancer Res Date: 2019-08-02 Impact factor: 12.531